SCHEMBL3812349

SCHEMBL3812349

CCCNC(=O)N(C)C1CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 16/20 0.47
CHRM4 P08173 1/20 0.44
GFER P55789 2/20 0.42
CASP6 P55212 1/20 0.42
CHRNA10 Q9GZZ6 1/20 0.41
CHRNA9 Q9UGM1 1/20 0.41
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
RAD52 P43351 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3636419 0.90 NPY5R (0.49) NPY5RGFERCASP6KDM4EGAA
SCHEMBL3635452 0.88 CHRNA10 (0.46) NPY5RCHRM4CHRNA10CHRNA9
SCHEMBL7287775 0.79 GFER (0.54) NPY5RGFERCASP6KDM4EGAA
SCHEMBL3123617 0.79 GFER (0.50) NPY5RGFERCASP6KDM4EGAA
SCHEMBL3635830 0.78 CHRNA7 (0.48) NPY5RCHRM4CHRNA10CHRNA9
SCHEMBL3666955 0.77 CHRM4 (0.45) NPY5RCHRM4KDM4EMAPTSMN1; SMN2
SCHEMBL30193146 0.76 LMNA (0.45) NPY5RGFERCASP6KDM4EGAA
SCHEMBL7299663 0.74 NPY5R (0.46) NPY5RGFERCASP6KDM4EGAA
SCHEMBL11310953 0.73 CHRM4 (0.58) CHRM4
SCHEMBL594199 0.72 GPR119 (0.46) NPY5RGFERCASP6KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-07-02 US disclosed
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-23 US disclosed
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors VIA PHARMACEUTICALS, INC. 2009-04-16 US disclosed
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT NPY5R 2744/4885CHRM4 4772/4885GFER 1433/4885
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT NPY5R 2744/4885CHRM4 4772/4885GFER 1433/4885
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT NPY5R 2744/4885CHRM4 4772/4885GFER 1433/4885
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT NPY5R 2744/4885CHRM4 4772/4885GFER 1433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.